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Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are major causes of liver disease
in Taiwan and have a great impact on the health of this country. This study investigated the sero-
prevalence of HBV and HCV in southern Taiwan. Screening programs were performed from
September 1999 to August 2005 for community-based surveillance of liver disease. A total of
28,797 adults from southern Taiwan, including Kaohsiung City (n = 14,036), Kaohsiung County
(n = 7,713), and Pingtung County (n = 7,048) were participated. The mean age was 50.3 ± 14.6 years
(range, 20–97 years), with 41.0% were men. Hepatitis B surface antigen (HBsAg), antibody to
HCV (anti-HCV), and liver function tests were performed. Among the 28,797 adults, the prevalence
of HBsAg(+) was 15.1% and that for anti-HCV(+) was 8.6%. The seroprevalence of HBsAg in
Kaohsiung County was 18.2%, which was higher than in Kaohsiung City (14.7%, p < 0.001) or
Pingtung County (12.5%, p < 0.001). The seroprevalence of anti-HCV in Kaohsiung County was
17.2%, which was higher than in the other regions (Kaohsiung City = 5.8%, p < 0.001; Pingtung
County = 4.6%, p < 0.001). The prevalence of dual HBsAg and anti-HCV was 1.1% (323 patients).
Tzukuan Township in Kaohsiung County was endemic for HBsAg (19.1%, 1,026/5,375 patients), anti-
HCV (22.4%, 1,203/5,375 patients), and dual HBsAg/anti-HCV (3.6%, 191/5,375 patients). Subjects
with anti-HCV(+) were older and had higher alanine transaminase levels than their HBsAg(+)
counterparts (p < 0.001 and p < 0.001, respectively). The current study shows the epidemiological
characteristics of HBV and HCV infections among adults in southern Taiwan. Viral hepatitis
infections remain widely endemic in this region.
Key Words: geographic variation, hepatitis B virus, hepatitis C virus, 
seroprevalence, Taiwan
(Kaohsiung J Med Sci 2010;26:461–9)
Hepatitis B virus (HBV) and hepatitis C virus (HCV)
infections are the leading causes of liver cirrhosis and
hepatocellular carcinoma (HCC) worldwide. The
World Health Organization estimates that 15–20% of
the world’s population has been infected with HBV,
and the prevalence of HCV has reached 3% globally.
These diseases therefore carry a subsequent risk of
patients developing end-stage liver disease and liver
cancer [1].
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Generally, end-stage liver disease and HCC, se-
quelae of HBV and HCV infections, are major health
problems in Taiwan. The prevalence of HBV infection
has reached 15–20% in the general population in
Taiwan, and is one of the highest in the world [2,3]. Our
previous study found a higher prevalence rate of HBV
infection in indigenous children in southern Taiwan
20 years after mass immunization programs were
launched in this country [4]. These results raised con-
cerns about the true geographic extent of HBV infection
in this area. In addition, although the seroprevalence of
HCV antibody (anti-HCV) nationwide is comparable
with that in Western countries, several townships that
are widely endemic for HCV infection have been dis-
covered in southern Taiwan as a result of the anti-HCV
test as well as efforts of public health personnel over
the past two decades [5–14]. Therefore, a wide and
comprehensive investigation is needed to assess the
seroprevalence characteristics of viral hepatitis in
southern Taiwan. Such data will pave the way for the
implementation of future epidemiological strategies.
Consequently, we conducted a mass screening pro-
gram to evaluate the seroprevalence of HBV and HCV
infections in southern Taiwan. The study was also
designed to elucidate the interactions between viral
hepatitis and related clinical profiles in this area.
METHODS
Screening projects and subjects
The community-based mass screening programs that
incorporated 127 instances of surveillance were per-
formed by investigators from Kaohsiung Medical
University Hospital and Kaohsiung Municipal Hsiao-
Kang Hospital in southern Taiwan. The geographic
area covered encompassed several townships, includ-
ing Kaohsiung City, Kaohsiung County, and Pingtung
County from September 1999 to August 2005 (Figure 1).
According to the 2005 National Statistical Database
of Taiwan, the total populations of Kaohsiung City,
Kaohsiung County, and Pingtung County were about
1,520,555, 1,244,313, and 889,563, respectively [15]. 
In collaboration with the local primary care centers,
almost all residents were notified by broadcasts, mail
or telephone of the opportunity to participate volun-
tarily in the study. A self-completed structured ques-
tionnaire was designed to identify possible routes of
infection among study participants. The risk factors
included transfusion, anti-HCV(+) family members,
surgery, medical injections or procedures (including
dental procedures), and other parenteral routes (in-
cluding acupuncture, tattoos, and body piercing). The
Institutional Review Board of Kaohsiung Medical
University Hospital approved the study before it
began.
Laboratory examinations
Serum alanine transaminase (ALT) levels were mea-
sured by an autoanalyzer (Hitachi, Tokyo, Japan). The
upper normal limit of ALT level is 34 IU/L. Hepatitis B
surface antigen (HBsAg) and anti-HCV were de-
tected using a second-generation or third-generation
commercially available enzyme-linked immunosor-
bent assay kit (AxSYM 3.0; Abbott Laboratories,
North Chicago, IL, USA). All anti-HCV-reactive sam-
ples were tested in duplicate and confirmed by HCV
RNA assay. Detection of serum HCV RNA was per-
formed using a standardized automated quantitative
reverse-transcription polymerase chain reaction
(COBAS AMPLICOR HCV Test, version 2.0; Roche,
Branchburg, NJ, USA). All the tests were performed
in duplicate. The detection limit was 50 IU/mL.
Statistical analysis
Fisher exact test or χ2 test were used to test the dif-
ference between prevalence rates of the groups. The
statistical tests were two-tailed and p < 0.05 was con-
sidered statistically significant. All procedures were
performed using SPSS version 12.0 (SPSS Inc., Chicago,
IL, USA).
RESULTS
Patients
A total of 28,797 residents living in southern Taiwan,
including 14,036 in Kaohsiung City, 7,713 in Kaohsiung
County, and 7,048 in Pingtung County, participated
in this screening program. The basic characteristics of
these individuals are shown in Table 1. Their mean
age was 50.3 ± 14.6 years (range, 20–97 years); 17,001
(59.0%) were women and 11,796 (41.0%) were men.
Seroprevalence of HBsAg(+) and 
anti-HCV(+)
The seroprevalence rates of HBsAg(+) and anti-
HCV(+) are shown in Table 2 and Figure 1. The overall
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Kaohsiung County (n = 2,338)
HBsAg(+): 13.3% (n = 312)
Anti-HCV(+): 3.8% (n = 89)
HBsAg(+) anti-HCV(+): 0.68% (n = 16)
Pingtung County (n = 7,048)
HBsAg(+): 12.5% (n = 880)
Anti-HCV(+): 4.6% (n = 322)
HBsAg(+) anti-HCV(+): 36.0% (n = 26)
Kaohsiung City (n = 14,036)
HBsAg(+): 14.7% (n = 2,067)
Anti-HCV(+): 5.8% (n = 819)
HBsAg(+) anti-HCV(+): 0.6% (n = 90)
Tzukuan Township (n = 5,375)
HBsAg(+): 19.1% (n = 1,026)
Anti-HCV(+): 22.4% (n = 1,203)
HBsAg(+) anti-HCV(+): 3.6% (n = 191)
T
Figure 1. Geographic locations and seroprevalence of HBsAg(+) and Anti-HCV(+) in southern Taiwan.
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frequencies of HBsAg(+) and anti-HCV(+) were 15.1%
(4,348/28,797) and 8.6% (2,465/28,797), respectively;
1,922 (78.0%) of these anti-HCV(+) serum samples were
positive using the COBAS AMPLICOR HCV Test. Of
the total 28,797 participants, 323 (1.1%) had dual pos-
itivity for HBsAg and anti-HCV. The seroprevalence of
HBsAg(+) in Kaohsiung County was 18.2%, which was
higher than that in Kaohsiung City (14.7%, p < 0.001)
and Pingtung County (12.5%, p<0.001). The seropreva-
lence of anti-HCV(+) in Kaohsiung County was 17.2%,
which was higher than that in Kaohsiung City (5.8%,
p < 0.001) and Pingtung County (4.6%, p < 0.001). The
frequency of HBsAg(+) was significantly higher among
men than women (17.6% vs. 13.4%, p < 0.001), whereas
the frequency of anti-HCV(+) was similar between men
and women (8.6% vs. 8.5%, p=0.79).
As shown in Table 3, Tzukuan Township in
Kaohsiung County had a higher seroprevalence of
HBsAg(+) (19.1%, 1,026/5,375) and a markedly higher
seroprevalence of anti-HCV(+) (22.4%, 1,203/5,375)
than any other townships in Kaohsiung County,
Kaohsiung City, and Pingtung County. After exclud-
ing subjects from Tzukuan Township, the overall
seroprevalence rates of HBsAg(+) and anti-HCV(+) in
Kaohsiung County were 13.3% (312/2,338) and 3.8%
(89/2,338), respectively. After excluding those subjects
in Tzukuan Township, the seroprevalence of HBsAg(+)
in Kaohsiung City was comparable with that found in
Kaohsiung County (14.7% vs. 13.3%, p=0.08) and was
significantly higher than that in Pingtung County
(14.7% vs. 12.5%, p<0.001). The seroprevalence of anti-
HCV(+) in Kaohsiung City was significantly higher
than that in Kaohsiung County and Pingtung County
(5.8% vs. 3.9% and 4.6%; p<0.001, p<0.001, respectively).
For different age groups classified by 10-year
intervals, the seroprevalence rates of HBsAg(+) and
anti-HCV(+) are shown in Figures 2 and 3. The peak
seroprevalence of HBsAg(+) occurred in subjects in
their 20s, and the prevalence declined gradually with
increasing age. After excluding Tzukuan Township,
the seroprevalence also declined gradually. In con-
trast to the HBsAg(+) group, the seroprevalence of
Table 1. Characteristics of the subjects recruited from different regions of southern Taiwan*
Kaohsiung City Kaohsiung County Pingtung County Total 
(n = 14,036) (n = 7,713) (n = 7,048) (n = 28,797)
Age (yr) 53.4 ± 12.7 (20–97) 41.3 ± 13.3 (20–91) 53.9 ± 15.3 (20–91) 50.3 ± 14.6 (20–97)
Sex, male 5,951 (42.4) 3,197 (41.4) 2,648 (37.6) 11,796 (41.0)
ALT (IU/L) 25.7 ± 28.7 27.1 ± 29.6† 21.8 ± 25.3 25.2 ± 28.3
*Data presented as mean ± standard deviation (range) or n (%); †significantly higher than other two regions, p < 0.001. ALT = alanine
transaminase.
Table 2. Seroprevalence and associated characteristics of hepatitis B and C patients in southern Taiwan*
HBsAg Anti-HCV
Positive Negative p Positive Negative p
No. of patients (%) 4,348 (15.1) 24,449 (84.9) 2,465 (8.6) 26,332 (91.4)
Age (yr) 47.3 ± 14.3 50.8 ± 14.6 < 0.001 53.9 ± 13.2 49.9 ± 14.7 < 0.001
Sex, male 2,072 (47.7) 9,724 (39.8) < 0.001 1,019 (41.3) 10,777 (40.9) 0.340
ALT (IU/L) 30.5 ± 38.7 24.2 ± 25.9 < 0.001 47.4 ± 52.3 23.1 ± 23.8 < 0.001
Geographic area
Kaohsiung City 2,067 (14.7) 11,969 (85.3) 819 (5.8) 13,217 (94.2)
Kaohsiung County 1,401 (18.2) 6,312 (81.8) 1,324 (17.2) 6,389 (82.8)
Pingtung County 880 (12.5) 6,168 (87.5) 322 (4.6) 6,726 (95.4)
*Data presented as n (%) or mean ± standard deviation. HBsAg = hepatitis B surface antigen; HCV = hepatitis C virus; ALT = alanine
transaminase.
Table 3. Prevalence and characteristics of viral hepatitis
infections in Kaohsiung County*
Tzukuan Township Townships except
(n = 5,375) Tzukuan (n = 2,338)
Sex, male 2,440 (45.4) 591 (25.3)
HBsAg(+) 1,026 (19.1) 312 (13.3)
Anti-HCV(+) 1,203 (22.4) 89 (3.8)
*Data presented as n (%). HBsAg = hepatitis B surface antigen;
HCV = hepatitis C virus.
simultaneous positivity of HBsAg and anti-HCV.
After excluding the patients in Tzukuan Township, the
seroprevalence rate of dual HBsAg(+) and anti-HCV(+)
was 0.68% in Kaohsiung County, which was compa-
rable with rates in Kaohsiung City and Pingtung
County. Patients with concurrent HBsAg(+) and anti-
HCV(+) were younger than those with anti-HCV(+)
alone, with respective mean ages of 50.1 ± 13.2 years
and 54.5 ± 13.1 years (p < 0.001); comparable with anti-
HCV(+) patients for ALT values (45.7 ± 47.0 IU/L vs.
47.8 ± 53.1 IU/L, p = 0.58); and significantly older with
higher ALT values than patients with HBsAg(+)
alone (47.2 ± 14.4 years, p = 0.002; 29.4 ± 39.7 IU/L,
p < 0.001, respectively). Similar to the age trend in the
anti-HCV(+) group, the concurrent HBsAg(+) and
anti-HCV(+) rates progressively increased from the
20–29-year age group to the 60–69-year age group in
Tzukuan Township, and increased from the 20–29-year
age group to the 50–59-year age group in other areas
in southern Taiwan (Figure 4).
Risk factors associated with HBsAg(+) and
anti-HCV(+)
After excluding those who were unwilling to answer
the questionnaires and eliminating incomplete ques-
tionnaires, 13,388 (46.5%) of 28,797 self-completed
structured questionnaires were collected to identify the
possible routes of infection among study participants.
Among those participants with HBsAg(+), 9.0% had
a history of blood transfusion; 35.0% had HBsAg(+)
family members; 1.2% had received injections or other
medical procedures; 1.4% had undergone acupuncture,
tattooing or body piercing; and 1.5% had undergone
previous surgery. No definite risk factors were identi-
fied in 52.0% of HBsAg(+) patients. In the anti-HCV(+)
group, 13.2% had a history of blood transfusion; 27.0%
had HCV(+) family members; 1.1% had received
Viral hepatitis in southern Taiwan
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Figure 2. Age-specific seroprevalence distribution of HBsAg(+)
with or without subjects from Tzukuan Township. HBsAg =
hepatitis B surface antigen.
Figure 3. Age-specific seroprevalence distribution of anti-
HCV(+) with or without subjects from Tzukuan Township.
HCV = hepatitis C virus.
Table 4. Demographic differences between different
viral hepatitis infections*
HBsAg(+) Anti-HCV(+) p
No. of patients (%) 4,025 (14.0) 2,142 (7.4)
Age (yr) 47.1 ± 14.3 54.5 ± 13.1 < 0.001
Sex
Male 1,920 (47.3) 849 (39.6) < 0.001
Female 2,123 (52.7) 1,293 (60.4)
ALT (IU/L) 29.3 (37.6) 47.7 (53.1) < 0.001
*Data presented as n (%) or mean±standard deviation. HBsAg=
hepatitis B surface antigen; HCV = hepatitis C virus; ALT =
alanine transaminase.
anti-HCV(+) seemed to increase with age. People with
anti-HCV(+) alone were older and had higher ALT
levels than those with HBsAg(+) alone (p < 0.001 and
p < 0.001), as shown in Table 4.
Dual seropositivity of HBsAg and anti-HCV
Dual seropositivity of HBsAg and anti-HCV was found
in 323 patients (overall = 1.1%, 323/28,797; Kaohsiung
City = 0.63%, 90/14,306; Kaohsiung County = 2.7%,
207/7,713; and Pingtung County = 0.37%, 26/7,048).
In Tzukuan Township, 3.6% (191/5,375) patients had
injections or other medical procedures; 1.3% had un-
dergone acupuncture, tattooing or body piercing; and
2.6% had a surgical history. Among the anti-HCV(+)
participants, 54.63% had no definite risk factors.
DISCUSSION
Viral hepatitis remains a significant worldwide pub-
lic health problem. HBV and HCV are the main causal
agents of chronic hepatitis and result in considerable
morbidity and mortality [16,17]. Further epidemiolog-
ical studies are therefore warranted for future imple-
mentation of strategies in public health. Apart from
the endemic situation of HBV infection in Taiwan, sev-
eral endemic areas have been discovered in southern
parts of the country, with the widespread application
of anti-HCV and HCV RNA tests over the past two
decades [13,18–22]. Therefore, there is a pressing need
to implement control measures in southern Taiwan,
with comprehensive elucidation of the characteristics
of viral hepatitis.
The current large-scale study demonstrated that the
prevalence of HBsAg(+) was 15.1%, which was com-
parable with rates in other parts of Taiwan [23]. After
excluding subjects in Tzukuan Township, the sero-
prevalence of HBsAg(+) in Kaohsiung City was sig-
nificantly higher than that in Pingtung County, and
the seroprevalence of anti-HCV(+) in Kaohsiung City
was significantly higher than that in Kaohsiung and
Pingtung Counties. There were significant geographic
differences in rates of HBsAg(+) and anti-HCV(+)
between Kaohsiung County, Kaohsiung City and
Pingtung County. The reasons for the geographic
variations in the seroprevalence of HBsAg(+) and
anti-HCV(+) are not known and require further inves-
tigation. Our study also found that the seroprevalence
of anti-HCV(+) reached 8.6% in southern Taiwan. In
addition, the hyperendemic status of HBV and HCV
infections in the Tzukuan region of Kaohsiung County
raises concern that further exploration of similar hy-
perendemic areas is needed to elucidate the charac-
teristic features in this region.
In Taiwan, most chronic carriage of HBV results
from infection in early childhood, especially before 
2 years of age [3,24]. We found that the seropreva-
lence of HBsAg(+) was 16.3–17.7% in the age groups
of 20–29 years, 30–39 years, and 40–49 years, and pro-
gressively declined in subjects over 50 years of age.
Our findings are consistent with those of Chen et al
[23]. At least two reasons explain this observation.
First, because the peak age of advanced HBV-related
liver diseases is 50–60 years, it is probable that some
HBV carriers had died of liver-related diseases after
age 50 years. Thus the percentage of HBsAg(+) de-
clined. Second, the carrier status is chronic, and
delayed HBsAg clearance contributes to decreased
seroprevalence of HBsAg after age 50 years [23,25].
In contrast to HBsAg, the rate of anti-HCV(+) 
progressively increased after age 20 years, which is
similar to previous studies [23,26]. The progressive
increase in HCV(+) seroprevalence with increasing
age was a common phenomenon in previous studies
[21,23]. Our results addressed the fact that HCV in-
fection is an acquired infectious disease and horizon-
tal infection is the major route of transmission. The
prevalence of HCV infection thus increases with age.
However, the routes of HCV transmission are not
fully understood and a large proportion of the victims
do not have identifiable risks of infection [5,27,28].
Therefore, cumulative risks of environmental agents
might contribute to the prevalence of HCV infection.
Future studies are required to ameliorate the endemic
situation in highly endemic areas.
According to the studies of Chen et al and others
[7–9,23], wide differences in HCV seroprevalence have
been found in different areas. The prevalence of HCV
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Figure 4. Age-specific seroprevalence distribution of dual
HBsAg(+) and anti-HCV(+) in different age groups in subjects from
Tzukuan Township and subjects excluding Tzukuan Township.
HBsAg = hepatitis B surface antigen; HCV = hepatitis C virus.
infection in northern Taiwan among adults has been
reported as 1.2–2.7% [7–9,23]. In our analysis, we found
that the seroprevalence of anti-HCV(+) was 8.6%.
Even if we excluded the people from the Tzukuan
area, where the seroprevalence rate of anti-HCV(+)
was 22.4%, the overall seroprevalence of anti-HCV
was 5.4% in southern Taiwan. The reasons for the dis-
parities in the general prevalence of HCV infection in
southern and northern Taiwan remain unclear. How-
ever, in our and other previous studies in southern
Taiwan, several HCV hyperendemic townships have
been discovered with anti-HCV(+) prevalence rates
of 15.0–57.9% [12,13]. The study of Ho and colleagues
has revealed that the importance of sexual or vertical
HCV transmission might be negligible, and having
received parenteral medication in local clinics is a
significant risk for HCV infection [11]. The HCV hyper-
endemic areas might be related to iatrogenic routes of
infection. Local culture and medical-seeking behav-
ior, such as frequent intravenous injections for minor
diseases or incomplete disinfection of medical equip-
ment in the past, might contribute to these high HCV
prevalence rates [13,23,26,29].
A total of 323 patients were simultaneously sero-
positive for HBsAg and anti-HCV. Tzukuan Town-
ship had significantly higher rates of concurrent
HBsAg(+) and anti-HCV(+) compared with other
southern Taiwanese areas (3.6% vs. 0.37–0.68%). One
of the novel findings of the current study demon-
strated that, in addition to its hyperendemic status
for HCV infection, Tzukuan Township carried the
highest prevalence of dual HBV and HCV infection
to date, to the best of our knowledge [30]. We demon-
strated that patients with dual HBV and HCV infec-
tion were significantly older and had higher ALT
values than those with HBV infection alone. Patients
with dual HBV and HCV infection seemed to have a
similar age trend as those with anti-HCV(+). The
older age of patients with dual HBV and HCV infec-
tion in our study agrees with findings in a previous
study [31], that is, increased superinfection of HCV on
top of chronic HBV carriage, and increased exposure to
HCV in elderly patients. Higher ALT values could be
caused by more severe hepatic damage [32,33]. The
significantly higher ALT levels in patients with concur-
rent HCV and HBV infection or HCV infection alone,
compared with HBV infection alone, imply an im-
portant pathogenic role for ALT levels in older persons
with chronic HCV infection. Superinfection of HCV in
HBV carriers is the common characteristic of dual HBV
and HCV infection in Taiwan, and results in suppres-
sion of HBV replication, which leads to a lower HBV
DNA level and a higher chance of HBsAg seroconver-
sion [30]. Further long-term follow-up study is neces-
sary to clarify the outcomes in this group of patients.
Although the current study recruited a large pop-
ulation for elucidation of the epidemiological features
of viral hepatitis in southern Taiwan, a common limi-
tation of epidemiological studies was present. The
open screening program relied on subjects volunteer-
ing to come forward. Thus the screened population
might not represent the true general population in
southern Taiwan. It is possible that more sick than
healthy people participated, which could have led to
overestimation of the prevalence of HBsAg(+) and
anti-HCV(+). Nevertheless, the current study ex-
cluded from the database those who received dupli-
cate examinations, which could have lessened the
confounding probability of the results. In addition,
the majority of screened cases in Kaohsiung County
came from Tzukuan Township. The true prevalence
might have been distorted by selection bias. The actual
prevalence of HBV and HCV in Kaohsiung County
must be explored further.
In conclusion, our study shows the current status
of epidemiological data about HBV and HCV infec-
tion among adults in southern Taiwan. HBV infection
is still endemic and the prevalence of anti-HCV is
higher than the prevalence in Northern Taiwan.
There are different demographic features in HBV and
HCV infection. The hyperendemic area for dual HBV
and HCV infection could raise awareness of this uni-
que issue in public health. Further efforts should be
made for prevention, early diagnosis, and treatment
of HBV- and HCV-related advanced liver disease and
HCC, to prevent further HCV infection.
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南台灣地區病毒性肝炎感染之血清盛行率：
一多中心參與之大型社區篩檢研究
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B型肝炎與 C型肝炎感染是台灣全國肝病盛行的主要原因，對國人健康威脅甚鉅。本研究
探討南台灣地區 B型肝炎與 C型肝炎病毒感染之血清盛行率。從 1999 年 9 月至 2005 年 8 
月共進行一系列總共 127 次肝病社區篩檢，總共 28,797 位成年（≥ 20歲），包括高雄市
（n = 14,036），高雄縣（n = 7,713），屏東縣（n = 7,048），參加我們的篩檢計劃。平均年
齡為 50.3 ± 14.6歲（20–97 歲），女性受檢者有 17,001 人（59%），男性受檢者有 11,796
人（41%），受檢者血液接受 B肝表面抗原（HBsAg）和 C型肝炎抗體（anti-HCV）檢
測。HBsAg 和 anti-HCV 的 總 體 陽 性 比 率 為 15.1%（4,348/28,797） 和 8.6%
（2,465/28,797）。高雄縣的 HBsAg血清盛行率為 18.2%，高於高雄市的 14.7%（p < 0.001）
和屏東縣的 12.5%（p < 0.001）。高雄縣的 anti-HCV 血清陽性盛行率為 17.2% 高於高雄
市的 5.8%（p < 0.001）和屏東縣的 4.6%（p < 0.001）。高雄縣的梓官鄉有較高的 HBsAg 
陽性血清盛行率（19.1%；1,026/5,375）還有明顯偏高的 anti-HCV 血清陽性盛行率
（22.4%；1,203/5,375）。在排除梓官鄉的受檢者之後，高雄縣的 HBsAg 和 anti-HCV 的血
清陽性盛行率是 13.3%（312/2,338）和 3.8%（89/2,338）。高雄市的 HBsAg 陽性血清盛
行率和排除梓官鄉受檢者之後的高雄縣相似（p = 0.08），高於屏東縣的 12.5%（p < 
0.001）。而高雄市的 anti-HCV 血清陽性盛行率高於排除梓官鄉受檢者之後的高雄縣和屏
東縣的 anti-HCV 血清陽性盛行率（5.8% vs. 3.9%，4.6%；p < 0.001, p < 0.001）HBsAg 陽
性血清盛行率隨著年齡增加而逐漸降低。相反地，anti-HCV 之陽性血清盛行率隨著年齡增
加而增加。單獨 anti-HCV 陽性之受檢者比單獨 HBsAg 陽性受檢者有明顯較高的年齡和較
高的 ALT 值（p < 0.001；p < 0.001）。總共有 323 位受檢者被發現為同時有 HBsAg 和 
anti-HCV 陽性（1.1%；323/28,797）其中包含梓官鄉 191 位受檢者同時有 HBsAg 和 anti-
HCV 陽性（3.6%；191/5,375）。HBsAg 和 anti-HCV 同時陽性受檢者比 HBsAg 單獨陽性
受檢者，年齡明顯較大（50.1 ± 13.2歲 vs. 47.2 ± 14.4歲； p = 0.002），ALT 值明顯較高
（45.7 ± 47.0 IU/L vs. 29.4 ± 39.7 IU/L；p < 0.001）。和 anti-HCV 陽性率一樣，HBsAg 
和 anti-HCV 同時陽性率隨著年齡增加而逐漸增加。
我們的研究提供了 B型肝炎病毒與 C型肝炎病毒感染在南台灣成人之流行病學資料：B
型肝炎感染在成年人依然盛行，而 anti-HCV 陽性之血清盛行率高於北台灣（1.2–2.7%）。
這些資料顯示，在南台灣 B型肝炎與 C型肝炎感染有不同的區域性特點。
關鍵詞：區域性特點，B型肝炎病毒，C型肝炎病毒，血清盛行率，台灣
（高雄醫誌 2010;26:461–9）
